Healix

Failure of Vedolizumab as First Line Biologic Does Not Decrease Response Rate of Second Line Therapy

Authors:
Timothy E. Ritter, MD – Texas Digestive Disease Consultants, PA, Southlake, TX
Chris Fourment, MD – Texas Digestive Disease Consultants, PA, Southlake, TX
Bitaal Sadiq, BS – Texas Digestive Disease Consultants, PA, Southlake, TX
Claudia P. Schroeder, PharmD, PhD – Healix Infusion Therapy, Sugar Land, TX
Tracy C. Okoro, PharmD – Healix Infusion Therapy, Sugar Land, TX
Lucinda J. Van Anglen, PharmD – Healix Infusion Therapy, Sugar Land, TX

View Poster

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.

FacebookTwitterLinkedInarrow1arcsearchiconowdtnotfound